1999 AAZV Proceedings.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

1999 AAZV Proceedings.Pdf DIAGNOSIS OF REPTILIAN VIRAL DISEASE Elliott R. Jacobson, DVM, PhD Department of Small Animal Clinical Sciences, Box 100126, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610 USA Abstract Starting in 1966 with the identification of the viral nature of intracytoplasmic inclusions in erythrocytes of geckos, more and more viruses have been identified as potential pathogens in reptiles. Many diseases originally thought to be bacterial in origin are now being recognized as viral diseases. Pneumonia that was first seen in a colony of vipers (Bothrops moojeni) was initially thought to be caused by Pseudomonas. Subsequent investigations identified the presence of a myxovirus and transmission studies have confirmed the pathogenic effect of these viruses. There is a very basic approach in determining the viral basis for a disease. The history of a die-off coupled with histopathologic findings may be suggestive. Ultimately, virus needs to be identified in tissues either by electron microscopy or by culturing the agent in tissue culture. Negative staining electron microscopy can be used to identify particles in feces, secretions, and tissue homogenates. Serology also has been used to determine exposure to a pathogen and PCR can be used to identify presence of specific nucleotide sequences in tissues or secretions of the host. Ultimately, virus needs to be cultured, purified and challenged back into naive animals to establish a causal relationship. Introduction Since 1966, a wide variety of viruses have been either identified in tissue section and/or isolated from members of the orders Chelonia (turtles and tortoises), Crocodylia (alligators, crocodiles, caiman, and gharial), and Squamata (Lacerta: lizards; Ophidia: snakes).5 An endogenous retrovirus is the only virus identified in Rhynchocephalia (tuatara).14 Most viruses identified in reptiles have been only circumstantially incriminated as causes of disease, and few studies fulfill Koch’s postulates. In many cases evidence of viral infection is based upon identification in tissue section by light microscopy, with more specific identification made using electron microscopy. Of the various viruses identified in reptiles, transmission studies demonstrating a causal relationship have only been documented for the gray patch herpesvirus of green turtles (Chelonia mydas) in aquaculture,10 ophidian (snake) paramyxovirus,7 and a retrovirus isolated from boid snakes with inclusion body disease.13 Most of the viruses identified in tissue section of reptiles have not been isolated and their role in reptile disease awaits further studies. In this paper I will review the various diagnostic approaches used in determining the presence of viruses in reptiles. 1999 PROCEEDINGS AMERICAN ASSOCIATION OF ZOO VETERINARIANS 1 Histopathology and Transmission Electron Microscopy While viruses have been isolated from tissues of reptiles without concomitant histopathology, often the isolation of viruses follows light microscopic findings suggestive of viral infection. Tissue specimens at necropsy are routinely collected in neutral buffered 10% formalin and if a viral infection is suspected, additional samples can be placed in Trump’s solution (a 4% formalin/1% glutaraldehyde mixture).8 If there is the potential of performing immunohistochemical staining such as for ophidian paramyxovirus, tissues should be transferred and stored in 70% ethanol at 24 to 48 hr following initial fixation.3 Frozen tissues can be collected for demonstration of viral antigen using antibody-labeled fluorescence microscopy. This has been used to demonstrate presence of ophidian paramyxovirus in lung tissue of infected snakes.7 Based upon light microscopic findings such as the presence of intranuclear inclusions in chelonian herpesvirus infections,9 or intracytoplasmic inclusions in boid inclusion body disease,13 the next step would be evaluation of tissues by transmission electron microscopy (TEM). While in TEM it is ideal to have tissues fixed in an appropriate fixative such as Trump’s solution or 2.5% glutaraldehyde, formalin fixed tissue and even paraffin embedded tissue can be examined for presence of virus. Sections of paraffin embedded tissue can be cut from a block using a scalpel blade, post-fixed, and submitted for TEM. The cost of TEM ranges from $100.00 to $200.00 per sample for processing, sectioning, examination, and photography. Based upon the size, location, morphology, and morphogenesis, a presumptive categorization into a family of virus often can be made. However, a final diagnosis is dependent upon biochemical characterization or determining specific nucleotide sequences using polymerase chain reaction. Negative Staining Electron Microscopy Negative staining in conjunction with TEM is a useful and rapid method of examining clinical specimens for presence of virus. The principle of negative staining is that there is no reaction between the stain and the specimen. The most commonly used negative stains are uranyl acetate (0.5-1.0%) and potassium phosphotungstate (PTA) (0.5-3.0%). Depending on the nature of the tissue, different ways of processing the sample are required to detect viral particles. Fluid from vesicles can be obtained with a sterile pipette and may be placed directly on a Formvar-coated 200 mesh copper grid, while large amounts of fluid (lung washings) require centrifugation for clarification. In these cases the supernatant after low speed centrifugation (1,500 g), or the diluted pellet after high speed centrifugation (15,000 g), is placed on the grid for staining. Fecal material requires suspension and concentration and should be placed in distilled water or phosphate buffered saline (PBS). Fecal material can be mixed with PBS to give a 20% suspension in 5 ml. After centrifuging, a drop of the supernatant is placed on a grid for examination. Cell Culture Viruses can be isolated from: 1) swab specimens of lesions or luminal surfaces; 2) tissue biopsies; and 3) tissues collected at necropsy. When biopsies or tissues are collected at necropsy, it is important to collect samples as aseptically as possible. Tissues can be placed in a sterile petri dish 2 1999 PROCEEDINGS AMERICAN ASSOCIATION OF ZOO VETERINARIANS and transported to the laboratory on ice, frozen in sterile plastic bags at -70°C for future viral isolation, or placed in cell culture media and frozen for future viral isolation attempts. Tissues should be sectioned into small pieces or ground in a tissue grinder, with cell culture media added. Processed samples are added to plastic cell culture flasks that contain actively dividing cells. Several reptile cell lines are commercially available from American Type Cell Culture (Bethesda, Maryland ) and include: 1) viper heart cells; 2) iguana heart cells; and 3) Terrapene heart cells. Cells are incubated at 30°C and are checked daily for cytopathic effects (CPE). Certain reptile viruses such as ophidian paramyxovirus have been adapted to mammalian Vero cells. This has certain advantages since it is possible to achieve faster growth of mammalian cells in culture compared to reptile cells. If changes are seen such as cell necrosis or syncytial cell formation, samples can be removed from a flask, fixed and processed for electron microscopy. Suspected viral antigen can be demonstrated in infected cells using a fluorescent antibody technique. This approach has been used for demonstrating the presence of ophidian paramyxovirus in infected viper heart cells.11 Serology Very few serologic tests have been developed or are available for diagnosing exposure of reptiles to specific viruses. Serologic studies have been performed on free-ranging reptiles and reptiles used in experimental studies in order to determine the presence of antibodies to various togaviruses.7 However, infections with these viruses do not appear to be clinically important in reptiles. A viral neutralization test has been developed to determine exposure of tortoises (Testudo hermanii and T. graeca) to a herpesvirus suspected of causing a stomatitis/pharyngitis.5 A hemagglutination inhibition (HI) assay has been developed to determine presence of antibody against ophidian paramyxoviruses.6,12 The HI assay has been most useful because of its relative simplicity and rapid “turnaround” time.2 Briefly, serum samples collected by heart puncture or tail venipuncture are diluted 1:10 in sterile physiologic saline at 56°C for 30 min to inactivate complement, then absorbed with washed and pelleted chicken erythrocytes to remove nonspecific agglutinins (12 hr at 5°C). Using microtiter methodology, serial doubling serum dilutions are made (1:10, 1:20, 1:40, 1:80, etc.) using 0.05 ml. volumes of phosphate buffered physiologic saline containing 0.1% bovine serum albumin. The latter minimizes autoagglutination of the erythrocyte suspension used later to indicate whether active virus is present or not. To each serum dilution is added an ophidian paramyxovirus suspension diluted to contain 8 hemagglutination units/0.05 ml. This has previously been determined by titration, taking advantage of the fact that the virus causes chicken erythrocytes to bind together (hemagglutinate). After allowing the virus-serum mixtures to interact for 1 hr at room temperature, 0.1 ml of a 0.3% suspension of washed chicken erythrocytes is added to each well of the microtiter plate. The plates are placed in a refrigerator for 2-3 hr to permit settling of the erythrocytes. If antibodies are present in a particular serum dilution, they will bind to
Recommended publications
  • Lindane Lotion USP, 1% RX Only WARNINGS
    Lindane Lotion USP, 1% RX Only WARNINGS: Lindane Lotion should only be used in patients who cannot tolerate or have failed first-line treatment with safer medications for the treatment of scabies. (See INDICATIONS AND USAGE.) Neurologic Toxicity Seizures and deaths have been reported following Lindane Lotion use with repeat or prolonged application, but also in rare cases following a single application used according to directions. Lindane lotion should be used with caution for infants, children, the elderly, and individuals with other skin conditions (e.g, atopic dermatitis, psoriasis) and in those who weigh < 110 lbs (50 kg) as they may be at risk of serious neurotoxicity. Contraindications Lindane Lotion is contraindicated in premature infants and individuals with known uncontrolled seizure disorders. Proper Use Instruct patients on the proper use of Lindane Lotion, the amount to apply, how long to leave it on, and avoiding re-treatment. Inform patients that itching occurs after the successful killing of scabies and is not necessarily an indication for re-treatment with Lindane Lotion. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION Lindane Lotion USP, 1%, is an ectoparasiticide and ovicide. In addition to the active ingredient, lindane, it contains glycerol monostearate, cetyl alcohol, stearic acid, trolamine, carrageenan, 2- amino-2-methyl-1-propanol, methylparaben, butylparaben, perfume and water to form a lotion. Lindane is the gamma isomer of 1,2,3,4,5,6-hexachlorocyclohexane having the following structural formula: C6H6Cl6 M.W. 290.83 CLINICAL PHARMACOLOGY Lindane Lotion USP, 1%, is an ectoparasiticide and ovicide effective against Sarcoptes scabiei (scabies). Lindane exerts its parasiticidal action by being directly absorbed into the parasites and 1 their ova.
    [Show full text]
  • Revised Use-Function Classification (2007)
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY IPCS INTOX Data Management System (INTOX DMS) Revised Use-Function Classification (2007) The Use-Function Classification is used in two places in the INTOX Data Management System: the Communication Record and the Agent/Product Record. The two records are linked: if there is an agent record for a Centre Agent that is the subject of a call, the appropriate Intended Use-Function can be selected automatically in the Communication Record. The Use-Function Classification is used when generating reports, both standard and customized, and for searching the case and agent databases. In particular, INTOX standard reports use the top level headings of the Intended Use-Functions that were selected for Centre Agents in the Communication Record (e.g. if an agent was classified as an Analgesic for Human Use in the Communication Record, it would be logged as a Pharmaceutical for Human Use in the report). The Use-Function classification is very important for ensuring harmonized data collection. In version 4.4 of the software, 5 new additions were made to the top levels of the classification provided with the system for the classification of organisms (items XIV to XVIII). This is a 'convenience' classification to facilitate searching of the Communications database. A taxonomic classification for organisms is provided within the INTOX DMS Agent Explorer. In May/June 2006 INTOX users were surveyed to find out whether they had made any changes to the Use-Function Classification. These changes were then discussed at the 4th and 5th Meetings of INTOX Users. Version 4.5 of the INTOX DMS includes the revised pesticides classification (shown in full below).
    [Show full text]
  • Antibiotics May Eradicate Gastrointestinal Immunodeficiency.8
    1122 Letters to the Editor J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.12.1122 on 1 December 1991. Downloaded from sitivity.? We present a case of OMM without pseudobulbar palsy. The association of vitro.8 Whipple's disease is associated with symptoms of Whipple's disease and with supranuclear gaze paresis with oculomas- immunodeficiency.8 Thus intestinal wall negative peroral jejunoileal biopsies, which ticatory myorhythmia, however, seems to be macrophages are ineffective in phagocytosing indicates the usefulness of laparotomy for pathognomonic of the effects of Whipple's intracellular gram positive bacilli, resulting in jejunoileal biopsies as an alternative to brain disease on the CNS.'2 This led us to perform inability to eliminate chronic infection.9 This biopsy to confirm Whipple's disease. surgical jejunal and mesenteric lymph node suggests that Whipple's disease may be con- A 47 year old woman was admitted in May biopsies rather than a brain biopsy despite sidered as a disease of macrophages.8 The 1988 in a depressed state. In June 1987 she negative endoscopic and numerous peroral periventricular and periaqueductal distribu- had noted progressive visual disturbance. distal jejunal and ileal biopsies. The nor- tion of the CNS involvement in Whipple's Rhythmic elevations of her right upper lip mality ofthe CT and MRI scans also suppor- disease consists of macrophagic infiltration appeared, and later, paroxysmal hypersomnia ted this decision. and subependymal nodules. Such a and considerable weight gain (10 kg). A nine The possibility of brain involvement with- "tumoural" involvement may explain why month course oftreatment for depression was out systemic manifestation in Whipple's dis- antibiotics with good BBB diffusion are not ineffective and her symptoms and signs ease should be kept in mind.
    [Show full text]
  • PASS Information
    H9X-MC-B010 Non-interventional PASS Final Study Report Page 1 PASS Information Title Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases Version identifier of the final study report Version 1.0 Date of last version of the final study report N/A EU PAS register number EUPAS13783 Active substance Dulaglutide (ATC code: A10BJ05) Medicinal product(s): Trulicity 0.75 mg solution for injection Trulicity 1.5 mg solution for injection Product reference: EU/1/14/956 Procedure number: EMEA/H/C/002825 Marketing authorisation holder(s) Eli Lilly Nederland B.V. Joint PASS No Research question and objectives The purpose of this study is to describe how dulaglutide is used among different patient groups in Europe. Primary objective: To describe the frequency of dulaglutide use in the population and characterise by age, gender, main comorbidities, and main co- prescriptions overall and in the following subgroups of interest: o Populations of interest: • Patients with severe renal failure • Patients with hepatic disease • Patients with heart failure • Patients with severe gastrointestinal disease • Children and adolescents (<18 years of age) • Elderly patients (≥75 years of age) • Pregnant or breast-feeding women o Medication use: • Medication errors • Off-label use Secondary objective: To describe the off-label use among each of the above populations of interest. Country(-ies) of study France, Germany, Spain, Sweden and the United Kingdom Author PPD Signature of principal investigator Signature on file/see approval date below Approval Date: 14-Nov-2019 GMT H9X-MC-B010 Non-interventional PASS Final Study Report Page 2 Marketing Authorisation Holder Marketing authorisation holder (MAH) Eli Lilly Nederland B.V.
    [Show full text]
  • A Saprolegnia Parasitica Challenge System for Rainbow Trout: Assessment of Pyceze As an Anti-Fungal Agent for Both Fish and Ova
    DISEASES OF AQUATIC ORGANISMS Published May 12 Dis Aquat Org l A Saprolegnia parasitica challenge system for rainbow trout: assessment of Pyceze as an anti-fungal agent for both fish and ova T. G.Pottinger*, J. G. Day NERC Institute of Freshwater Ecology, Windermere Laboratory, Far Sawrey, Ambleside, Cumbria, LA22 OLP, United Kingdom ABSTRACT: A reproducible Saprolegnia parasitica spore delivery system was developed and demon- strated to be effective in providing a sustained spore challenge for up to 10 d. Treatment of rainbow trout with slow-release intraperitoneal implants containing cortisol resulted in chronically elevated blood cortisol levels and rendered the fish susceptible to infection by S. parasitica when exposed to the spore challenge. Sham-implanted fish were not susceptible to infect~on.Bronopol (2-bromo-2-nitro- propane-1,3-dol), formulated as Pyceze, was effective in protecting predisposed fish from infection by S. parasitica when administered as a daily bathlflush treatment at concentrations of 15 mg I-' and greater. Pyceze was also demonstrated to protect fertilised rainbow trout ova from S. parasitica chal- lenge when administered as a daily bath/flush treatment at concentrations of between 30 and 100 mg 1-l. Pyceze appears to qualify as a safe and effective replacement for malachite green and formalin in the prevention of fungal infections in the aquaculture environment. KEY WORDS: Saprolegnia . Fungal infection . Salmonid . Bronopol - Pyceze . Cortisol INTRODUCTION chite green in combating mycotic infections of fish and fish eggs, but is safer for the operator, the fish, and Mycotic infections of farmed fish, primarily by water the environment. Among the alternative compounds moulds or pseudofungi of the genus Saprolegnia, rep- tested for antifungal activity are sodium chloride resent a significant economic and welfare problem.
    [Show full text]
  • A Single Amino Acid Substitution in the Third Transmembrane Region Has Opposite Impacts on the Selectivity of the Parasiticides
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/09/08/mol.117.109413.DC1 1521-0111/92/5/546–555$25.00 https://doi.org/10.1124/mol.117.109413 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:546–555, November 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics A Single Amino Acid Substitution in the Third Transmembrane Region Has Opposite Impacts on the Selectivity of the Parasiticides Fluralaner and Ivermectin for Ligand-Gated Chloride Channels s Yunosuke Nakata, Toshinori Fuse, Kohei Yamato, Miho Asahi, Kunimitsu Nakahira, Fumiyo Ozoe, and Yoshihisa Ozoe Faculty of Life and Environmental Science, Shimane University, Matsue, Shimane, Japan (Y.N., T.F., K.Y, F.O., Y.O.); and Downloaded from Biological Research Laboratories, Nissan Chemical Industries, Ltd., Saitama, Japan (M.A., K.N.) Received May 16, 2017; accepted September 9, 2017 ABSTRACT Fluralaner (Bravecto) is a recently marketed isoxazoline ectopar- transmembrane region (TM3) with an aromatic amino acid molpharm.aspetjournals.org asiticide. This compound potently inhibits GABA-gated chloride dramatically enhanced the potency of fluralaner in the GluCls. channels (GABACls) and less potently glutamate-gated chloride In stark contrast to the enhancement of fluralaner potency, this channels (GluCls) in insects. The mechanism underlying this mutation eliminated the activation of currents and the potenti- selectivity is unknown. Therefore, we sought to identify the ation but not the antagonism of glutamate responses that are amino acid residues causing the low potency of fluralaner toward otherwise all elicited by the macrolide parasiticide ivermectin GluCls. We examined the fluralaner sensitivity of mutant housefly (IVM).
    [Show full text]
  • Study Protocol
    STUDY PROTOCOL FOR COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR 35% PEROX-AID® (HYDROGEN PEROXIDE) FOR THE CONTROL OF ECTOPARASITES (INAD #11-669) Sponsor: U.S. Fish and Wildlife Service, Division of the National Fish Hatchery System ______________________ ___________________ Sponsor Signature Date Approved Manufacturer: Eka Chemicals Inc. 1775 West Oak Commons Court Marietta, Georgia 30062-2254 Facility for Coordination of 35% PEROX AID® INAD: Aquatic Animal Drug Approval Partnership Program 4050 Bridger Canyon Road Bozeman, Mt 59715 Proposed Starting Date: December 1, 2007 Proposed Ending Date: November 30, 2012 Study Director: Mr. Jim Bowker _________________________ ________________ Study Director Signature Date Clinical Field Trial Location and Trial Number: Facility ______________________________________________________________ Type or Print Name Investigator____________________________________________________________ Type or Print Name __________________________________________ ________________________ Investigator Signature Date 1 I. STUDY ID AND TITLE 3 II. SPONSOR 3 III. INVESTIGATORS/FACILITIES 4 IV. PROPOSED STARTING AND COMPLETION DATES: 4 V. BACKGROUND/PURPOSE 4 VI. SPECIFIC OBJECTIVES 6 VII. MATERIALS 7 VIII. EXPERIMENTAL UNIT 10 IX. ENTRANCE CRITERIA 10 X. TREATMENT GROUPS 11 XI. TREATMENT SCHEDULES 12 XII. TREATMENT RESPONSE PARAMETERS 15 XIII. FORMS FOR DATA COLLECTION 15 XIV. RECORD KEEPING PROCEDURES 16 XV. DISPOSITION OF INVESTIGATIONAL ANIMALS 16 XVI. DISPOSITION OF INVESTIGATIONAL
    [Show full text]
  • Other Contributions
    Other Contributions NATURE NOTES Amphibia: Anura Incilius luetkenii, Smilisca sordida, and Lithobates forreri. Predation by birds. Predation on adult anurans by tropical birds has been recorded on numerous occasions, where birds of various families (e.g., Accipitridae, Striigidae, Momotidae, Turdidae) have preyed on anurans of different families (e.g., Centrolenidae, Dendrobatidae, Hylidae, Leptodactylidae, Rhinophrynidae; Hayes, 1983; Master 1999; Toledo et al., 2007; Acosta and Morún, 2014; Ramírez-Fernández and Solís-DelValle, 2014). The majority of these events are opportunistic and associated with diet-generalist or invertebrate- and vertebrate-predator bird species (Toledo et al., 2007; Amézquita et al., 2013; Paluh et al., 2015). Here, we present information on the predation of Incilius luetkenii (Bufonidae), Smilisca sordida (Hylidae), and Lithobates forreri (Ranidae) by birds in Costa Rica. On 26 May 2013, at Área de Conservación Guanacaste, Sector Santa Rosa, Provincia de Guanacaste, Costa Rica (10°50'N, 85°37'W; WGS 84; elev. 298 m), we observed a Roadside Hawk (Buteo [Rupornis] magnirostris) feeding on an individual of Incilius luetkenii. The hawk was standing on the ground pecking and eating a dead I. luetkenii along the edge of gravel road in Tropical Dry Forest, but once it was startled flew across the road without the toad and perched on a tree approximately 5 m from the ground. We cannot determine if the hawk captured the toad or found it dead (the toad remains appeared fresh), but either of these behaviors was likely because the previous evening breeding aggregations involving I. luetkenii had occurred in the area. Although frogs and toads are import- ant dietary items for this hawk (Haverschmidt, 1972; Beltzer, 1990), this observation is the first to report I.
    [Show full text]
  • Laboratory and Field Studies to Investigate the Efficacy of a Novel
    Kryda et al. Parasites Vectors (2019) 12:445 https://doi.org/10.1186/s13071-019-3702-6 Parasites & Vectors RESEARCH Open Access Laboratory and feld studies to investigate the efcacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Diroflaria immitis) in dogs Kristina Kryda1*, Robert H. Six1, Kelly F. Walsh1, Susan J. Holzmer1, Sara Chapin1, Sean P. Mahabir1, Melanie Myers1, Tammy Inskeep1, Jady Rugg1, Blair Cundif1, Aleah Pullins1, Michael Ulrich2, John W. McCall3, Tom L. McTier1 and Steven J. Maeder1 Abstract Background: Diroflaria immitis is a flarial parasite of dogs that can cause serious or fatal cardiopulmonary disease. Three studies were conducted to evaluate the efcacy and safety of monthly treatment with moxidectin in a chew- able tablet product in combination with sarolaner and pyrantel to prevent heartworm disease in dogs after experi- mental challenge and in a clinical feld study in the USA. Methods: In two laboratory studies, dogs (8 per group) that had been inoculated 30 days prior with 50 third-stage D. immitis larvae were randomized to treatment on Day 0 with placebo or combination product, at the minimum dose of 24 µg/kg moxidectin, 2 mg/kg sarolaner and 5 mg/kg pyrantel (as pamoate salt). Study 2 also included groups treated with tablets containing moxidectin-alone (24 µg/kg) or sarolaner-alone (2 mg/kg). Efcacy was evaluated ~ 5 months after inoculation by adult heartworm counts at necropsy. In the feld study, 410 dogs 8 weeks-old from 23 USA veterinary clinics were treated for 11 months with either combination product at 24–48 µg/kg≥ moxidectin, 2–4 mg/kg sarolaner and 5–10 mg/kg pyrantel (n 272) or Heartgard® Plus (ivermectin/pyrantel) at the label recom- mended dose rate (n 138).
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Armand Bayou Watershed Plan Cover: Top Left Photo Courtesy Armand Bayou Nature Center; All Other Photos © Cliff Meinhardt Armand Bayou Watershed Plan Phase I
    Armand Bayou Watershed Plan COVER: TOP LEFT PHOTO COURTESY ARMAND BAYOU NATURE CENTER; ALL OTHER PHOTOS © CLIFF MEINHARDT Armand Bayou Watershed Plan Phase I A Report of the Coastal Coordination Council Pursuant to National Oceanic and Atmospheric Administration Award No. NA170Z1140 Production of this document supported in part by Institutional Grant NA16RG1078 to Texas A&M University from the National Sea Grant Office, National Oceanic and Atmospheric Administration, U.S. Department of Commerce, and a grant from ExxonMobil Coporation ii PHOTO © CLIFF MEINHARDT Contents Acknowledgements .......................................................................................................................................................1 Executive Summary .......................................................................................................................................................2 Introduction .............................................................................................................................................................2 The Armand Bayou Watershed Partnership ..................................................................................................................2 State of the Watershed ..............................................................................................................................................2 Institutional Framework ..............................................................................................................................................3
    [Show full text]
  • BULLETIN Chicago Herpetological Society
    BULLETIN of the Chicago Herpetological Society Volume 53, Number 8 August 2018 BULLETIN OF THE CHICAGO HERPETOLOGICAL SOCIETY Volume 53, Number 8 August 2018 Notes on the Herpetofauna of Western Mexico 19: An Update to the Herpetofauna of Volcán de Tequila in Jalisco, Mexico . .Juan Rubén Rojo-Gutiérrez, David Jaimes-Rodríguez, Daniel Cruz-Sáenz, Laura López-Fernández, Enrique Chávez-Uribe and David Lazcano 165 Toad Stools: Part Two . Dennis A. Meritt Jr. 170 The Digital Age and Herp Lit: An Evolving Playing Field in the New Millennium . R. Michael Burger 171 Deputy Louie . Roger A. Repp 174 What You Missed at the June Meeting: Daniel Parker . .John Archer 178 Herpetology 2018......................................................... 181 Advertisements . 184 New CHS Members This Month . 184 Cover: Coral-bellied ring-necked snake, Diadophis punctatus pulchellus, Tuolumne County, California. Photograph by Stephen L. Barten, DVM. STAFF Membership in the CHS includes a subscription to the monthly Bulletin. Annual dues are: Individual Membership, $25.00; Editor: Michael A. Dloogatch --- [email protected] Family Membership, $28.00; Sustaining Membership, $50.00; Copy editor: Joan Moore Contributing Membership, $100.00; Institutional Membership, $38.00. Remittance must be made in U.S. funds. Subscribers 2017 CHS Board of Directors outside the U.S. must add $12.00 for postage. Send membership dues or address changes to: Chicago Herpetological Society, President: Rich Crowley Membership Secretary, 2430 N. Cannon Drive, Chicago, IL 60614. Vice-president: Jessica Wadleigh Treasurer: John Archer Manuscripts published in the Bulletin of the Chicago Herpeto- Recording Secretary: Gail Oomens logical Society are not peer reviewed. Manuscripts and letters Media Secretary: Kim Klisiak concerning editorial business should be e-mailed to the editor, Membership Secretary: Mike Dloogatch [email protected].
    [Show full text]